Invention Grant
US08258260B2 Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
有权
与人类白细胞抗原（HLA）II类分子有明显结合的肿瘤相关肽
- Patent Title: Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
- Patent Title (中): 与人类白细胞抗原（HLA）II类分子有明显结合的肿瘤相关肽
-
Application No.: US11942561Application Date: 2007-11-19
-
Publication No.: US08258260B2Publication Date: 2012-09-04
- Inventor: Jörn Dengjel
- Applicant: Jörn Dengjel
- Applicant Address: DE Tubingen
- Assignee: Immatics Biotechnologies GmbH
- Current Assignee: Immatics Biotechnologies GmbH
- Current Assignee Address: DE Tubingen
- Agency: Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
- Priority: EP05019254 20050905
- Main IPC: A61K35/14
- IPC: A61K35/14
Abstract:
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.
Public/Granted literature
- US20110150849A1 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules Public/Granted day:2011-06-23
Information query
IPC分类:
